Targeted selection of HIV-specific antibody mutations by engineering B cell maturation-Reference-Cited by-同舟云学术

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Published:2019-12-06 Issue:6470 Volume:366 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Saunders Kevin O.¹²³^ORCID,Wiehe Kevin⁴^ORCID,Tian Ming⁵^ORCID,Acharya Priyamvada¹^ORCID,Bradley Todd⁴^ORCID,Alam S. Munir⁴^ORCID,Go Eden P.⁶,Scearce Richard⁴^ORCID,Sutherland Laura⁴^ORCID,Henderson Rory⁴^ORCID,Hsu Allen L.⁷^ORCID,Borgnia Mario J.⁷^ORCID,Chen Haiyan⁴,Lu Xiaozhi⁴,Wu Nelson R.⁴^ORCID,Watts Brian⁴,Jiang Chuancang⁴,Easterhoff David⁴,Cheng Hwei-Ling⁵,McGovern Kelly⁵^ORCID,Waddicor Peyton⁵^ORCID,Chapdelaine-Williams Aimee⁵,Eaton Amanda⁴^ORCID,Zhang Jinsong⁴,Rountree Wes⁴^ORCID,Verkoczy Laurent⁴,Tomai Mark⁸^ORCID,Lewis Mark G.⁹^ORCID,Desaire Heather R.⁶,Edwards Robert J.⁴^ORCID,Cain Derek W.⁴^ORCID,Bonsignori Mattia⁴^ORCID,Montefiori David¹^ORCID,Alt Frederick W.⁵^ORCID,Haynes Barton F.³⁴^ORCID

Affiliation:

1. Human Vaccine Institute and Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.

2. Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.

3. Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.

4. Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

5. Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.

6. Department of Chemistry, University of Kansas, Lawrence, KS 66049, USA.

7. Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC 27709, USA.

8. Corporate Research Materials Lab, 3M Company, St. Paul, MN 55144, USA.

9. Bioqual, Rockville, MD 20850, USA.

Abstract

Engineering better bnAbs A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197

Funder

National Institute of Allergy and Infectious Diseases

Duke University

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference93 articles.

1. Developing an HIV vaccine

2. The quest for an antibody-based HIV vaccine

3. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

4. HIV-Host Interactions: Implications for Vaccine Design

5. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microsecond dynamics control the HIV-1 Envelope conformation;Science Advances;2024-02-02

2. Prophylactic HIV-1 vaccine trials: past, present, and future;The Lancet HIV;2024-02

3. Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds;Nature Communications;2024-01-30

4. Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens;Biotechnology Advances;2024-01

5. Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques;Cell;2024-01